Edwards Lifesciences CFO Sells $1M in Shares Edwards Lifesciences' CFO sold $1.0m of stock per an SEC Form 4 filed Apr 9, 2026 (Investing.com); institutional investors should verify Form 4 details before drawing conclusions.

Edwards Lifesciences CFO Sells $1M in Shares: Edwards Lifesciences' CFO sold $1.0m of stock per an SEC Form 4 filed Apr 9, 2026 (Investing.com); institutional investors should verify Form 4 details before drawing… 👈 Read full analysis #EdwardsLifesciences #CFO #StockMarket #InsiderTrading #Investing

Edwards Lifesciences Shares Rise 12% YTD on TAVR Growth Edwards Lifesciences reported FY2025 revenue of $6.2bn (+8% YoY); shares are up ~12% YTD as the TAVR market projects a 7.8% CAGR to 2030 (sources: Edwards, Grand View Research).

Edwards Lifesciences Shares Rise 12% YTD on TAVR Growth: Edwards Lifesciences reported FY2025 revenue of $6.2bn (+8% YoY); shares are up ~12% YTD as the TAVR market projects a 7.8% CAGR to 2030… Read full analysis 👉 #EdwardsLifesciences #TAVR #HealthcareInnovation #MedicalDevices #InvestmentNews

FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve (Reuters) -The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp (NYSE:EW)’s acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition. Edwards and JenaValve are the only two companies in the U.S. currently conducting clinical trials on transcatheter aortic valve replacement devices, which are used to treat a condition called aortic regurgitation where the heart’s aortic valve does not close properly, the FTC said in its lawsuit. Edwards said it "disagrees with FTC’s decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation." It expects a final outcome by early 2026. Edwards announced the deal in July 2024, along with its acquisition of another heart valve maker, Endotronix. The deals, together valued at approximately $1.2 billion, were aimed at expanding its portfolio of structural heart disease treatments. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is EW one of them?

Click Subscribe #FTC #EdwardsLifesciences #JenaValve #MergerNews #AcquisitionBlock

Edwards Lifesciences stock rises following competitor’s exit EWBSX hereremove ads Latest comments Install Our AppScan QR code to install app Google Play App Store Blog Mobile Portfolio Widgets About Us Advertise Help & Support Authors Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #EdwardsLifesciences #Investing #StockMarket #AorticValve #BostonScientific

Percutaneous Mitral Valve Repair with the PASCAL Ace System in an Older Patient with a Dislocated Annuloplasty Ring: The First Case Report in Italy First Italian case of percutaneous mitral valve repair with PASCAL Ace system in an elderly patient with a dislocated annuloplasty ring and severe regurgitation

First Italian case of percutaneous #MitralValveRepair with #PASCALAce in an elderly patient with a dislocated annuloplasty ring. A promising #minimallyinvasive solution.

#openaccess: bit.ly/3DQBopZ

#MitralRegurgitation #Cardiology #EdwardsLifesciences @scienceopen.bsky.social

Percutaneous Mitral Valve Repair with the PASCAL Ace System in an Older Patient with a Dislocated Annuloplasty Ring: The First Case Report in Italy First Italian case of percutaneous mitral valve repair with PASCAL Ace system in an elderly patient with a dislocated annuloplasty ring and severe regurgitation

First Italian case of percutaneous #MitralValveRepair with #pascalace in an elderly patient with a dislocated annuloplasty ring. A promising #MinimallyInvasive solution.

#openaccess: cvia-journal.org/percutaneous...

#mitralregurgitation #cardiology #EdwardsLifesciences

Thank you to the #EdwardsLifesciences Foundation for the beautiful reception celebrating our NPO’s in Orange County. It was an honor to represent CAPOC and CHIOC as a board member for both organizations. Looking forward to the work ahead in 2025. #EradicatingPoverty